Table 1 Patient and disease characteristics of the entire cohort (n = 193)
Variable | Results |
|---|---|
Male/female | 83/110 |
Age at diagnosis, median (IQR) | 32 (21–44) |
Age at initiation TG, median (IQR) | 43 (33–56) |
Hospital | |
▪ St. Thomas’ Hospital | 87 (45%) |
▪ East Surrey Hospital | 67 (35%) |
▪ Queen Elizabeth Hospital | 39 (20%) |
Crohn’s disease (Montreal classification) | 123 (64%) |
Age at diagnosis | |
▪ < 17 (A1) | 16 (19%) |
▪ 17–40 (A2) | 71 (58%) |
▪ > 40 (A3) | 29 (24%) |
Location | |
▪ Ileal (L1) | 38 (31%) |
▪ Colonic (L2) | 15 (15%) |
▪ Ileocolonic (L3) | 62 (50%) |
▪ Upper gastrointestinal disease (L4) | 4 (3%) |
Behaviour | |
▪ Nonstricturing, nonpenetrating (B1) | 45 (40%) |
▪ Stricturing (B2) | 36 (33%) |
▪ Penetrating (B3) | 26 (27%) |
▪ Perianal disease (p) | 23 (12%) |
Ulcerative colitis (Montreal classification) | 64 (33%) |
Extent | |
▪ Proctitis (E1) | 18 (30%) |
▪ Left-sided (E2) | 24 (37%) |
▪ Pancolitis (E3) | 21 (33%) |
Severity | |
▪ Asymptomatic (S0) | 9 (14%) |
▪ Mild (S1) | 15 (24%) |
▪ Moderate (S2) | 18 (28%) |
▪ Severe (S3) | 22 (34%) |
IBD unclassified | 6 (3%) |
Drug failure prior to thioguanine initiation | 193 (100%) |
▪ Azathioprine | 123 (58%) |
▪ Mercaptopurine | 11 (5%) |
▪ Azathioprine and mercaptopurine | 59 (27%) |
▪ Azathiopurine and allopurinol | 76 (39%) |
▪ Anti-tumour necrosis factor | 77 (40%) |
▪ Methotrexate | 36 (19%) |
▪ Tacrolimus | 8 (4%) |
Gastrointestinal surgery prior to thioguanine initiation | 63 (33%) |
Follow-up in months, median (IQR) | 36 (22–53) |
Treatment duration of thioguanine (months, IQR) | 23 (10–47) |